Division of BioTherapeutics
Cardiovascular and Metabolic Therapeutics
This research group, headed by Miranda van Eck, focusses on understanding the molecular mechanisms underlying cardiovascular and metabolic diseases. Cardiovascular disease constitutes a major health issue worldwide. Although significant knowledge has been obtained on the development of atherosclerotic lesions and disturbances in lipid metabolism that underlies cardiovascular disease pathology, current treatments are only able to stop the progression of the disease, reducing mortality by only 25-30%. The overall ambition of the group of Van Eck is to identify novel targets for intervention in cardiovascular and metabolic disease and develop novel therapeutic strategies directly targeting macrophages in atherosclerotic lesions and improving lipid metabolism.
Miranda van Eck studied Bio-Pharmaceutical Sciences, specializing in Biopharmaceutics at the University of Leiden in The Netherlands. After her graduation in 1994 she obtained her PhD from Leiden University in 1999 on the use of the bone marrow transplantation technique as a novel strategy to study the role of macrophage genes in lipoprotein metabolism and atherogenesis. She is an expert in HDL metabolism and reverse cholesterol transport from the arterial wall to the liver and the role of ABC-transporters and scavenger receptor BI in this process. Her current research has extended to the identification of the role of novel genes in atherosclerotic lesion development, regression of atherosclerosis, and processes underlying the development of atherothrombosis.
Van Eck has over 120 publications in major international peer-reviewed scientific journals, that are frequently cited, indicating a wide international recognition. The h-index, an index that measures both the scientific productivity and the apparent scientific impact, for her publications is >40. Apart from attracting many citations, her work has led to a great number of international collaborations with consequently collaborative publications and invitations for key lectures at international meetings, including Gordon Conferences. Furthermore, it has led to several successful grant applications, including highly competitive VIDI (2005) and VICI (2013) Innovational Research grants from the Netherlands Organization for Scientific Research. Van Eck has received several prestigious awards, including the Galenus Research Prize which recognizes innovative pharmaceutical research in the Netherlands and twice an award from the International HDL Research Award Program for outstanding investigators in the field of HDL biology. Furthermore, since 2008, Van Eck is recognized as an Established Investigator by the Netherlands Heart Foundation. She is associate editor of “Atherosclerosis” and member of the editorial board of “Arteriosclerosis, Thrombosis, and Vascular Biology”.
Since 2012, Miranda van Eck is also acting member of the LACDR Board of Directors and Management Team. From 2012-2019, she was Programme Director of the Bachelor and Master programmes Bio-Pharmaceutical Sciences at Leiden University. As of September 2019 she is fully focussing on the Master programme Bio-Pharmaceutical Sciences as Programme Director.
This video can not be shown because you did not accept cookies.You can leave our website to view this video.
Research expertise and facilities
The research group of Miranda van Eck is specialized in experimental models of atherosclerosis and metabolic disease. There is long-standing expertise for studying macrophage function using amongst others the bone marrow transplantation techniques, as well as adrenal transplantation, and in vivo therapeutic intervention strategies. A wide array of techniques ranging from genomic analysis and in vitro cellular studies to advanced microscopy, histology, laser-capture microdissection and FACS analysis of tissues and cells are applied.